Literature DB >> 33786682

Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.

Xin Lou1, Juan-Juan Wang2, Ya-Qing Wei1, Ying-Jie He1, Zhi-Jia Jiang1, Jin-Jin Sun3.   

Abstract

Although various molecular subtypes of hepatocellular carcinoma (HCC) have been investigated, most of these studies identify HCC subtype based on genomic profiling. Few studies have investigated the classification based on immune signatures, and none have classified HCC based on Immune activation and immunosuppressive. We performed immune gene expression of tumor tissue in 374 HCC patients from The Cancer Genome Atlas (TCGA) database and used unsupervised consensus clustering to stratify tumors. We then used HCC patients from the International Cancer Genome Consortium (ICGC) and Gene Expression Omnibus (GEO) as replication datasets. Based on the expression of 782 immune-related genes, HCC was stratified into four distinct immune subtypes. Tumors in one cluster (high immune activation; high-IA) indicate a higher level of Immune activation, which was characterized by higher anti-tumor immunity, higher pro-tumor immune-suppressive cell types, higher fractions of CD8+ T cells and M0 Macrophages compared with other subtypes. The high-IA also presents higher cancer-related hallmark signatures, such as epithelial-mesenchymal transition (EMT), angiogenesis, and apoptosis. We also found subpopulations of regulatory and exhaustion T lymphocyte were characterized by an opposite trend in high-IA, though samples in high-IA response to immunotherapy with better survival. The comparison of the immune profile in tumor and normal tissue indicates the activation of immune responses which only occurred in high-IA patients, while we conducted comparison of cirrhosis and non-cirrhosis tumor immune signatures, immune response activation was almost occurred in high-IA, but some of immune responses occurred in low-IA (low immune activation).

Entities:  

Keywords:  Cancer-related hallmark signature; Immune activation; Immune subtypes; Immunosuppressive; Mutations landscape

Year:  2021        PMID: 33786682     DOI: 10.1007/s12032-021-01499-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  40 in total

1.  Changes in insulin, glucagon and ER stress precede immune activation in type 1 diabetes.

Authors:  Jennifer A Crookshank; Daniel Serrano; Gen-Sheng Wang; Christopher Patrick; Baylie S Morgan; Marie-France Paré; Fraser W Scott
Journal:  J Endocrinol       Date:  2018-11-01       Impact factor: 4.286

Review 2.  The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.

Authors:  Andrea Huwiler; Uwe Zangemeister-Wittke
Journal:  Pharmacol Ther       Date:  2017-11-08       Impact factor: 12.310

3.  Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses.

Authors:  Kung-Chao Chang; Guan-Cheng Huang; Dan Jones; Ya-Hui Lin
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

4.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors:  Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

5.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Authors:  Etienne Becht; Nicolas A Giraldo; Laetitia Lacroix; Bénédicte Buttard; Nabila Elarouci; Florent Petitprez; Janick Selves; Pierre Laurent-Puig; Catherine Sautès-Fridman; Wolf H Fridman; Aurélien de Reyniès
Journal:  Genome Biol       Date:  2016-10-20       Impact factor: 13.583

6.  Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.

Authors:  Anna Morena D'Alise; Guido Leoni; Gabriella Cotugno; Fulvia Troise; Francesca Langone; Imma Fichera; Maria De Lucia; Lidia Avalle; Rosa Vitale; Adriano Leuzzi; Veronica Bignone; Elena Di Matteo; Fabio Giovanni Tucci; Valeria Poli; Armin Lahm; Maria Teresa Catanese; Antonella Folgori; Stefano Colloca; Alfredo Nicosia; Elisa Scarselli
Journal:  Nat Commun       Date:  2019-06-19       Impact factor: 14.919

Review 7.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Authors:  T A Chan; M Yarchoan; E Jaffee; C Swanton; S A Quezada; A Stenzinger; S Peters
Journal:  Ann Oncol       Date:  2019-01-01       Impact factor: 32.976

8.  GSVA: gene set variation analysis for microarray and RNA-seq data.

Authors:  Sonja Hänzelmann; Robert Castelo; Justin Guinney
Journal:  BMC Bioinformatics       Date:  2013-01-16       Impact factor: 3.169

9.  Pan-cancer deconvolution of tumour composition using DNA methylation.

Authors:  Ankur Chakravarthy; Andrew Furness; Kroopa Joshi; Ehsan Ghorani; Kirsty Ford; Matthew J Ward; Emma V King; Matt Lechner; Teresa Marafioti; Sergio A Quezada; Gareth J Thomas; Andrew Feber; Tim R Fenton
Journal:  Nat Commun       Date:  2018-08-13       Impact factor: 14.919

10.  Classification of triple-negative breast cancers based on Immunogenomic profiling.

Authors:  Yin He; Zehang Jiang; Cai Chen; Xiaosheng Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.